Cencora (COR) Earnings Date & Reports

Key Takeaways

• Cencora, Inc. (COR) is scheduled to report its fourth quarter and full-year fiscal 2026 results on Wednesday, November 4, 2026, before the market opens.
• Wall Street expects adjusted earnings per share (EPS) of roughly $4.52 to $4.58, up from $3.84 in the prior-year quarter.
• Consensus revenue estimates center around $87.97 billion, compared with $83.73 billion a year ago.
• Investors will watch U.S. Healthcare Solutions volume trends, specialty drug performance, and GLP-1 sales contributions.
• Cencora has topped consensus EPS estimates in seven of its last eight quarters, a track record that shapes sentiment heading into the report.
• For additional detail on this ticker, explore its Major News, Today's Price Move, Price Targets, and Forecast pages.
• To discover other high-momentum setups, explore Trending AI Robots.

Earnings Context and Why It Matters

Cencora is one of the largest pharmaceutical distributors in the world, connecting manufacturers, pharmacies, and healthcare providers across the U.S. and international markets. Because its fiscal year ends on September 30, the upcoming report serves as both a fourth-quarter update and a full-year scorecard for fiscal 2026. The results will show whether the company sustained the volume-driven revenue growth and margin expansion that have defined its recent quarters, including the contribution from its Retina Consultants of America (RCA) acquisition. For investors, the report is also a key checkpoint on full-year guidance, specialty drug momentum, and the trajectory of GLP-1 product sales, which have been a meaningful but variable contributor to top-line growth.

Earnings Expectations

Analysts expect Cencora to report adjusted EPS between roughly $4.52 and $4.58 for the fourth quarter of fiscal 2026, up from $3.84 in the same period a year earlier. Consensus revenue estimates sit near $87.97 billion, compared with $83.73 billion in the prior-year quarter. On a full-year basis, management has guided adjusted EPS to a range of $17.75 to $17.95, raised from its initial fiscal 2026 outlook. Key metrics investors will watch include U.S. Healthcare Solutions segment revenue and operating income, the contribution from specialty and GLP-1 products, adjusted gross margin, and any update to the company's long-term adjusted operating income and EPS growth targets. Cencora has beaten consensus EPS estimates in seven of its last eight quarters, a pattern that raises the bar for this report.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. By surfacing trade ideas, trending names, breakout candidates, and market opportunities more efficiently than manual screening, the screener helps investors focus their research where it matters most. Explore the AI Screener to build a watchlist tailored to your strategy.

Market Reaction and Investor Sentiment

Sentiment heading into the print is generally constructive, supported by Cencora's consistent history of earnings beats and its raised fiscal 2026 guidance. Still, the stock has shown sensitivity to quarterly reports, and the company's heavy reliance on low-margin distribution revenue means investors focus closely on profitability metrics rather than headline sales growth alone. Key risk factors include any slowdown in prescription volume growth, softer GLP-1 contribution, pressure in the international segment's consulting and specialty logistics businesses, and ongoing opioid-related litigation accruals that can distort reported (GAAP) results. Because the prior-year quarter included litigation-related items that weighed on GAAP results, investors will likely emphasize the company's adjusted, non-GAAP figures when evaluating performance.

Forward Outlook and Key Factors to Monitor

Beyond the headline numbers, investors should watch management's commentary on the fiscal 2027 outlook and whether long-term growth targets remain intact. Cencora has previously signaled adjusted operating income growth of 6% to 9% and adjusted EPS growth of 9% to 13% over the long term, so any reaffirmation or revision of these targets will be closely scrutinized.

Specialty distribution and the integration of Retina Consultants of America are also worth monitoring, given their outsized impact on gross margin expansion. The company has leaned on specialty products to offset thin margins in traditional pharmaceutical distribution, and continued momentum here could support profitability even as revenue growth moderates.

On the demand side, prescription utilization trends and the contribution from GLP-1 medications remain important swing factors. While GLP-1 sales add meaningful revenue, their profitability contribution is more limited, so investors will parse whether volume gains are translating into higher operating income. Finally, watch cost trends, interest expense tied to acquisition financing, and any updates on share repurchases, all of which can shape adjusted EPS growth in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations